Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 3/20 | 0.45 |
| ▸ | CES1 | P23141 | 3/20 | 0.45 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heptane SCHEMBL10683139 | 0.96 | TSHR (0.59) | TSHRALDH1A1THRBLMNAMEN1 | |
| Hexane SCHEMBL7995860 | 0.96 | TSHR (0.56) | TSHRALDH1A1THRBLMNAMEN1 | |
| Hexane SCHEMBL7540084 | 0.96 | TSHR (0.56) | TSHRALDH1A1THRBLMNAMEN1 | |
| Hexane SCHEMBL9430852 | 0.96 | TSHR (0.56) | TSHRALDH1A1THRBLMNAMEN1 | |
| Hexane SCHEMBL398717 | 0.96 | TSHR (0.56) | TSHRALDH1A1THRBLMNAMEN1 | |
| Hexane SCHEMBL27549779 | 0.92 | TSHR (0.53) | TSHRALDH1A1THRBLMNAMEN1 | |
| Hexane SCHEMBL2394206 | 0.92 | TSHR (0.53) | TSHRALDH1A1THRBLMNAMEN1 | |
| Heptane SCHEMBL219891 | 0.92 | TSHR (0.73) | TSHRALDH1A1THRBLMNAMEN1 | |
| Heptane SCHEMBL8891016 | 0.92 | TSHR (0.73) | TSHRALDH1A1THRBLMNAMEN1 | |
| Decane SCHEMBL16931705 | 0.92 | TSHR (0.73) | TSHRALDH1A1THRBLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102649803-A | Preparation process for extracting and separating high-purity Cyasterone | SUZHOU BAOZETANG MEDICAL TECH | 2012-08-29 | — | — | CN | claimed |
| CN-102649803-A | Preparation process for extracting and separating high-purity Cyasterone | SUZHOU BAOZETANG MEDICAL TECH | 2012-08-29 | — | — | CN | disclosed |
| EP-2252372-A1 | 2-AMINOQUINOLINES | F. Hoffmann-La Roche AG (CH) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009109502-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| US-6992097-B2 | Growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050143318-A1 | Growth hormone secretagogues | DODGE JEFFREY A (US) | 2005-06-30 | — | — | US | disclosed |
| US-20040122234-A1 | Growth Hormone secretagogues | HAUSER KENNETH LEE (US) | 2004-06-24 | — | — | US | disclosed |
| US-6639076-B1 | Such as 2-(2-amino-2-methylpropanoylamino)-n-(1-(2-oxo-1-phenyl-2-pyrrolidinylethyl -4-yl)-4-phenylbutanamide | ELI LILLY AND COMPANY | 2003-10-28 | — | — | US | disclosed |
| EP-0948483-B1 | FARNESYL TRANSFERASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2002-03-13 | — | — | EP | disclosed |
| US-6329342-B1 | CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY | 2001-12-11 | — | — | US | disclosed |
| CN-1242000-A | Farnesyl transferase inhibitors | RHONE POULENC RORER SA (FR) | 2000-01-19 | — | — | CN | disclosed |
| EP-0948483-A1 | FARNESYL TRANSFERASE INHIBITORS | Aventis Pharma S.A. (FR) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998029390-A1 | FARNESYL TRANSFERASE INHIBITORS | RHONE-POULENC RORER S.A. (FR) | 1998-07-09 | — | — | WO | disclosed |
| US-4851441-A | Antiviral guanidine derivatives compositions and their methods of use | HARBOR BRANCH OCEANOGRAPHIC INSTITUTION, INC. (US) | 1989-07-25 | — | — | US | disclosed |
| US-4772609-A | Antiviral guanidine derivatives and compositions therefor | HARBOR BRANCH OCEANOGRAPHIC INSTITUTION, INC. (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0271571-A1 | ANTIVIRAL GUANIDINE DERIVATIVE COMPOSITIONS AND THEIR METHODS OF USE | HARBOR BRANCH OCEANOGRAPHIC INSTITUTION, INC. (US) | 1988-06-22 | — | — | EP | disclosed |
| WO-1988000181-A1 | ANTIVIRAL GUANIDINE DERIVATIVE COMPOSITIONS AND THEIR METHODS OF USE | HARBOR BRANCH OCEANOGRAPHIC INSTITUTION, INC. (US) | 1988-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143318-A1 | Growth hormone secretagogues | GHSR, GHRHR, SSTR3 | TSHR 28/4885ALDH1A1 4506/4885THRB 134/4885 |
| US-20040122234-A1 | Growth Hormone secretagogues | GHSR, GHRHR, CRH | TSHR 40/4885ALDH1A1 4382/4885THRB 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.